Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1999-04-09
2000-01-11
Elliott, George C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 245, 536 231, 536 232, 536 243, 536 2433, 435 6, 435 911, 435 9131, 435325, 435375, 514 44, C07H 2104, C07H 2102, C12N 1511, A61K 4800, A61K 3500
Patent
active
060137886
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of Smad3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad3. Methods of using these compounds for modulation of Smad3 expression and for treatment of diseases associated with expression of Smad3 are provided.
REFERENCES:
patent: 5149797 (1992-09-01), Pederson
patent: 5789573 (1998-08-01), Baker
patent: 5856462 (1999-01-01), Agrawal
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, Feb. 1998.
Eugene Uhlmann and Anusch Peyman, Antisense Oligonucleotides: A new Therapeutic Principle, Chemical Reviews, pp. 545-546, Jun. 1990.
Trisha Gura, Antisense Has Growing Pains, Science, pp. 575-577, Oct. 1995.
Stanley Crooke, Antisense '97: A roundtable on the state of the industry, Nature Biotechnology, p. 522, Jun. 1997.
Dennler et al., Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene, Embo J., 1998, 17:3091-3100.
Feng et al., The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation, Genes Dev., 1998, 12:2153-2163.
Hahn et al., Recent discoveries in cancer genetics of exocrine pancreatic neoplasia, Digestion, 1998, 59:493-501.
Heldin et al., TGF-beta signalling from cell membrane to nucleus through SMAD proteins, Nature, 1997, 390:465-471.
Kretzschmar et al., SMADs: mediators and regulators of TGF-beta signaling, Curr. Opin. Genet. Dev., 1998, 8:103-111.
Mucsi et al., Dominant-negative SMAD-3 interferes with transcriptional activation by multiple agonists, Biochem. Biophys. Res. Commun., 1997, 232:517-521.
Picon et al., A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1, Cancer Epidemiol. Biomarkers Prev., 1998, 7:497-504.
Saltis et al., Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease, Clin. Exp. Pharmacol. Physiol., 1996, 23:193-200.
Wrana, TGF-beta receptors and signalling mechanisms, Miner. Electrolyte Metab., 1998, 24:120-130.
Zawel et al., Human Smad3 and Smad4 are sequence-specific transcription activators, Mol. Cell, 1998, 1:611-617.
Zhang et al., Receptor-associated Mad homologues synergize as effectors of the TGF-beta response, Nature, 1996, 383:168-172.
Zhang et al., Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription, Nature, 1998, 394:909-913.
Zhao et al., Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture, Dev. Biol., 1998, 194:182-195.
Cowsert Lex M.
Monia Brett P.
Elliott George C.
Epps Janet
Isis Pharmaceuticals , Inc.
LandOfFree
Antisense modulation of Smad3 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of Smad3 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of Smad3 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1463453